

Cinpanemab ELISA Kit

Summary

Catalog No.	KDE22001
Alternative Names	BIIB-054, CAS: 2094516-02-4
Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection method	Colorimetric
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity	0.156 µg/ml
Range	0.31-5 µg/mL
Recovery	80-120%
Shipping	2-8 °C
Note	For Research Use Only.

Background

Cinpanemab is a human-derived monoclonal antibody directed against α -synuclein. Genetic and pathology evidence implicate this protein in the molecular pathogenesis of Parkinson's disease (PD) and other α -synucleinopathies such as dementia with Lewy bodies (DLB). In 2010, Biogen licensed cinpanemab from Neurimmune. The antibody was generated with reverse translational medicine technology from naturally occurring, presumably protective antibodies found in healthy aged donors, as were aducanumab and other antibodies in the Biogen-Neurimmune partnership. The antibody, previously

Recombinant Proteins & Antibodies

known as BIIB054, binds to α -synuclein residues 1-10, with 800-fold higher affinity for aggregated over monomeric α -synuclein. The antibody inhibits α -synuclein spreading in cell-based assays, and slows pathology and motor symptoms in mice (Weihofen et al., 2019).

Precision

CV<20%

Data Image
